Author Description

The COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. Additionally, the therapeutic efficacy of existing anti-infective agents is often limited due to sub-optimal biopharmaceutical properties, sub-therapeutic levels of the drugs at the infection site due to various physiological barriers, the expulsion of the drug by efflux transporters, and the emergence of drug-resistant strains.From the commercialization of AmBisome® to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization ofexisting armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. While there are several books dedicated to pharmaceutical and/or biomedical applications of nanotechnology or nanotechnology for cancer therapy a comprehensive book focusing on the prevention and/or treatment of viral, bacterial, fungal, and parasitic infections is not available. This book addresses an unmet need in pharmaceutical and medical education. This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, funga